Promoter methylation status and expression levels of rassf1a gene in different phases of acute lymphoblastic leukemia (All) by Sohani, Mahsa et al.
IJHOSCR 
International Journal of Hematology-Oncology and Stem Cell Research 
 
Copyright © 2021 Tehran University of Medical Sciences. This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International 
license (http:// creativecommons.org/licenses/by-nc/4.0). Non-commercial uses of the work are permitted, provided the original work is properly cited.  
 
     
 
Original Article 
IJHOSCR 15(1) - ijhoscr.tums.ac.ir – January, 1, 2021 
Promoter Methylation Status and Expression Levels 
of RASSF1A Gene in Different Phases of Acute 
Lymphoblastic Leukemia (ALL) 
 
Mahsa Sohani1, Shahrbano Rostami2, Mehdi Azad3, Tahereh Hojjatipour1, Bahram Chahardouli2, Shaban 
Alizadeh1 
 
1Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran 
²Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran 
 ³Department of Medical Laboratory Sciences, School of Paramedicine, Qazvin University of Medical Sciences, Qazvin, Iran 
 
Corresponding Author: Shaban Alizadeh, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Tehran 




  Received: 09, Dec, 2019 
                                                                                                                                                                                                                   Accepted: 17, May, 2020 
 
ABSTRACT 
Background: Although the precise pathogenesis of acute lymphoblastic leukemia (ALL) remains unclear, 
studying gene-regulating mechanisms during ALL pathogeneses may shed light on the underlying mechanisms 
driving malignant behavior. There is some evidence showing the promoter hypermethylation and silencing of 
RASSF1A tumor suppressor gene in ALL cells; however, there is a lack of evidence for whether the gene 
indeed alters during different phases of ALL or in response to therapy. Thus, the current study aimed to clarify 
this issue using groups of adult ALL patients who have been scarcely investigated regarding expression levels 
and promoter methylation status. 
Materials and Methods: In this case/control study, the expression levels and methylation status of the gene 
promoter was evaluated using quantitative real-time PCR and methylation-specific PCR (MSP), respectively in 
adults with ALL. The study included peripheral blood of patients with newly diagnosed ALL (n=10), complete 
remission (CR) (n=10), or relapse (n=10), and 10 control samples from healthy individuals. 
Results: MSP results revealed an unmethylated status for almost all patients and control samples, except a 
case with relapsing ALL, which showed a hemimethylated pattern. RASSF1A also showed no difference in 
terms of gene expression in the patients compared with the control group (p>0.05).  
Conclusion: The results revealed an up-regulation of RASSF1A tumor suppressor in adult ALL patients 
experiencing CR, suggesting this to be a marker of therapy response. However, further investigations using 
more sensitive methylation detecting tools with larger sample sizes may better clarify the involvement of the 
promoter methylation of RASSF1A in these patients.  
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  Acute lymphoblastic leukemia (ALL) is 
characterized by the excessive accumulation of 
lymphoblasts and lymphoid progenitors. Although 
ALL is the most common type of leukemia in 
children (25%), there is also a peak of incidence in 
adults1. The disease had been regarded incurable 
until 1970, which caused fatal consequences in the 
affected individuals2. A novel therapeutic 
development could overcome the irreversible 
